| Name | Title | Contact Details |
|---|
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, we are committed to changing the lives of people with these life-threatening conditions. Across the organization, our team is united by our passion for making a difference, and committed to pushing ideas as far and as fast as possible. The needs of people living with rare diseases are at the center of our inventive science, our commercial organization, and our clinical programs. Every member of the Amicus Therapeutics team works to make a meaningful difference for the communities that we serve. Several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. Our global footprint spans 27 countries, including our global headquarters in Cranbury, NJ and international headquarters in Gerrards Cross UK. Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, The Netherlands, and Spain.
Our partner practices, including Barnet Dulaney Perkins Eye Center, Southwestern Eye Center, Retinal Consultants of Arizona, M&M Eye Institute, Abrams Eye Institute, Havasu Eye Center and Visage Aesthetics and Plastic Surgery have on average been in p...
Paragon 28 was established for unmet needs of the foot and ankle community. Dedicated to creating solutions to improve the treatment of foot and ankle conditions.
Healthpoint Biotherapeutics is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kyorin USA is a Teaneck, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.